Ruian Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ruian Xu has a total of 161 co-authors. Here are the top co-authors by number of shared publications:
- Yong Diao
School of Medicine, Huaqiao University, Quanzhou 362021, China
9 shared publications Mingqing Tang
Engineering Research Centre of Molecular Medicine of Ministry of Education, Fujian Key Laboratory of Molecular Medicine, Key Laboratory of Precision Medicine and Molecular Diagnosis of Fujian Universities, Xiamen Key Laboratory of Marine and Gene Drugs, School of Biomedical Sciences, Huaqiao University, Xiamen, Fujian, China
6 shared publications- Xiuling Cui
Engineering Research Centre of Molecular Medicine of Ministry of Education, Key Laboratory of Fujian Molecular Medicine, Key Laboratory of Precision Medicine and Molecular Diagnosis of Fujian Universities, Key Laboratory of Xiamen Marine and Gene Drugs, School of Biomedical Sciences, Huaqiao University, Xiamen 361021, P. R. China
4 shared publications - Mingqing Tang
Medical School, Huaqiao University, Quanzhou, China
3 shared publications Qi-Zhao Wang
3 shared publicationsQizhao Wang
3 shared publications
Latest Publications
- Open Access
- 24 April 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-19
A facultative plasminogen-independent thrombolytic enzyme from Sipunculus nudus
Current thrombolytic therapies primarily function by converting plasminogen into plasmin, a process dependent on the fibrin–activator complex. This dependence, coupled with the substantial molecular size of plasmin, constrains its effectiveness in degrading D-dimer and restricts its diffusion within thrombi. Here, we introduce a small facultative plasminogen-independent thrombolytic enzyme, snFPITE, isolated from Sipunculus nudus. Compared to traditional thrombolytic agents, snFPITE does not require plasminogen for thrombolysis, although its presence enhances lytic activity. This enzyme fully degrades cross-linked fibrin without leaving residual nondegradable D-dimer and generates a smaller fibrinolytic-active agent from plasminogen. A series of male rats and mice models further confirm that snFPITE is a safety injectable thrombolytic agent. Mechanistically, snFPITE activates plasminogen and degrades fibrin(ogen) in a multisite cleavage manner. snFPITE is inhibited by plasminogen activator inhibitor 1 and α2-antiplasmin via a competitive inhibition. We further identify 28 snFPITE candidate sequences, of which 10 are confirmed as functional genes.
- 24 April 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-19
Open AccessA facultative plasminogen-independent thrombolytic enzyme from Sipunculus nudus
Current thrombolytic therapies primarily function by converting plasminogen into plasmin, a process dependent on the fibrin–activator complex. This dependence, coupled with the substantial molecular size of plasmin, constrains its effectiveness in degrading D-dimer and restricts its diffusion within thrombi. Here, we introduce a small facultative plasminogen-independent thrombolytic enzyme, snFPITE, isolated from Sipunculus nudus. Compared to traditional thrombolytic agents, snFPITE does not require plasminogen for thrombolysis, although its presence enhances lytic activity. This enzyme fully degrades cross-linked fibrin without leaving residual nondegradable D-dimer and generates a smaller fibrinolytic-active agent from plasminogen. A series of male rats and mice models further confirm that snFPITE is a safety injectable thrombolytic agent. Mechanistically, snFPITE activates plasminogen and degrades fibrin(ogen) in a multisite cleavage manner. snFPITE is inhibited by plasminogen activator inhibitor 1 and α2-antiplasmin via a competitive inhibition. We further identify 28 snFPITE candidate sequences, of which 10 are confirmed as functional genes.
- Open Access
- 20 July 2023
- Published by Springer Nature in Research Square
A novel type of facultative and plasminogen independent thrombolytic enzyme from the ancient marine organism, Sipunculus nudus
Thrombotic diseases have become a leading threat to global health, especially in the post-COVID-19 era. Current thrombolytic drugs are highly dependent on the activation of the human plasminogen. Herein we disclose a novel facultative and plasminogen independent thrombolytic enzyme (snFPITE) from Sipunculus nudus, which could completely dissolve fibrin(ogen) into ultra-small molecule fragments without leaving any undegradable D-dimer. Furthermore, it cleaves the plasminogen to form a new fibrinolytic-active agent (Flaa) rather than the conventional plasmin. Mechanistically, snFPITE activates the plasminogen and degrades fibrin(ogen) at multiple cleavage sites, and this plasminogen activation and fibrin(ogen) degradation are inhibited by plasminogen activator inhibitor 1 and α2-antiplasmin through a unique competitive inhibition mechanism. On the other hand, up to 29 snFPITE candidate sequences have been identified by mass spectroscopy, molecular cloning and genome sequencing, including 10 of which that have been functionally verified. This novel thrombolytic enzyme pool might be valuable for the rapid development of powerful and efficient thrombolytic drugs in the near future.
- 20 July 2023
- Published by Springer Nature in Research Square
Open AccessA novel type of facultative and plasminogen independent thrombolytic enzyme from the ancient marine organism, Sipunculus nudus
Thrombotic diseases have become a leading threat to global health, especially in the post-COVID-19 era. Current thrombolytic drugs are highly dependent on the activation of the human plasminogen. Herein we disclose a novel facultative and plasminogen independent thrombolytic enzyme (snFPITE) from Sipunculus nudus, which could completely dissolve fibrin(ogen) into ultra-small molecule fragments without leaving any undegradable D-dimer. Furthermore, it cleaves the plasminogen to form a new fibrinolytic-active agent (Flaa) rather than the conventional plasmin. Mechanistically, snFPITE activates the plasminogen and degrades fibrin(ogen) at multiple cleavage sites, and this plasminogen activation and fibrin(ogen) degradation are inhibited by plasminogen activator inhibitor 1 and α2-antiplasmin through a unique competitive inhibition mechanism. On the other hand, up to 29 snFPITE candidate sequences have been identified by mass spectroscopy, molecular cloning and genome sequencing, including 10 of which that have been functionally verified. This novel thrombolytic enzyme pool might be valuable for the rapid development of powerful and efficient thrombolytic drugs in the near future.
- Open Access
- 29 June 2023
- Published by Walter de Gruyter GmbH in Oncologie
- Vol. 25 (5) , 507-517
The effect of ubiquitin-specific peptidase 21 on proliferation, migration, and invasion in DU145 cells
Objectives Although ubiquitin-specific peptidase 21 (USP21) has been shown to promote the development of various cancers, its role in prostate cancer has been poorly reported. Therefore, this study attempted to investigate the involvement of USP21 in prostate adenocarcinoma (PRAD) progression. Methods Information from public databases was used to evaluate the pattern of USP21 expression in PRAD tissues and its effect on patient prognosis. Subsequently, we either upregulated or knocked down USP21 expression in the human PRAD cell line DU145 to assess cell growth, migration, invasiveness, and apoptosis. Results The transcript levels of USP21 in PRAD tissues were low, indicating a poor prognosis. In DU145 cells, USP21 silencing impaired cell proliferation, colony formation, cell cycle progression, migratory capacity, and invasiveness, while it increased rates of apoptosis. Furthermore, cell proliferation, migration, and invasion were all induced by upregulating USP21. In addition, gene enrichment analysis revealed that USP21 had the potential to regulate cell adhesion and the cell cycle. This observation was further validated by the detection of expression of related genes in cells with either knockdown or increased USP21 expression levels. The expression and copy numbers of USP21 were significantly correlated with the infiltration levels of immune cells. Conclusions Expression level of USP21 is associated with PRAD progression and poor prognosis, and may have a role in potential therapeutic strategies for patients with PRAD.
- 29 June 2023
- Published by Walter de Gruyter GmbH in Oncologie
- Vol. 25 (5) , 507-517
Open AccessThe effect of ubiquitin-specific peptidase 21 on proliferation, migration, and invasion in DU145 cells
Objectives Although ubiquitin-specific peptidase 21 (USP21) has been shown to promote the development of various cancers, its role in prostate cancer has been poorly reported. Therefore, this study attempted to investigate the involvement of USP21 in prostate adenocarcinoma (PRAD) progression. Methods Information from public databases was used to evaluate the pattern of USP21 expression in PRAD tissues and its effect on patient prognosis. Subsequently, we either upregulated or knocked down USP21 expression in the human PRAD cell line DU145 to assess cell growth, migration, invasiveness, and apoptosis. Results The transcript levels of USP21 in PRAD tissues were low, indicating a poor prognosis. In DU145 cells, USP21 silencing impaired cell proliferation, colony formation, cell cycle progression, migratory capacity, and invasiveness, while it increased rates of apoptosis. Furthermore, cell proliferation, migration, and invasion were all induced by upregulating USP21. In addition, gene enrichment analysis revealed that USP21 had the potential to regulate cell adhesion and the cell cycle. This observation was further validated by the detection of expression of related genes in cells with either knockdown or increased USP21 expression levels. The expression and copy numbers of USP21 were significantly correlated with the infiltration levels of immune cells. Conclusions Expression level of USP21 is associated with PRAD progression and poor prognosis, and may have a role in potential therapeutic strategies for patients with PRAD.
- Open Access
Novel Ferrocene Derivatives Induce Apoptosis through Mitochondria-Dependent and Cell Cycle Arrest via PI3K/Akt/mTOR Signaling Pathway in T Cell Acute Lymphoblastic Leukemia
T cell acute lymphoblastic leukemia (T-ALL) is one of the most common causes of death in pediatric malignancies. However, the clinical chemotherapy for T-ALL has been limited by numerous side effects, emphasizing that novel anti-T-ALL drugs are urgently needed. Herein, a series of 2-acyl-1-dimethylaminomethyl-ferrocenes for cancer therapy have been evaluated. Among them, F1 and F3 exhibited potent cytotoxicity against T-ALL cell lines, especially Jurkat cells, with low cytotoxicity for normal cells. Further mechanistic studies revealed that F1 and F3 could induce apoptosis in Jurkat cells by destructing mitochondrial membrane, enhancing reactive oxygen species (ROS) generation, decreasing the Bcl-2/Bax ratio, releasing Cytochrome c, and increasing the expression of Cleaved Caspase-9/-3 and Cleaved PARP. Additionally, F1 and F3 could suppress cell proliferation and arrest the cell cycle at G0/G1 phase through the PI3K/Akt/mTOR signaling pathway by down-regulating the expression of CDK6, Cyclin D1, p-Akt, p-GSK-3β, p-mTOR, p-p70 S6K, and up-regulating the expression of P21 and P27, which would also be a possible mechanism. Consequently, ferrocene derivatives F1 and F3 could induce apoptosis through a mitochondria-dependent pathway mediated by ROS, and cell cycle arrest at G0/G1 phase via the PI3K/Akt/mTOR signaling pathway in Jurkat cells. The present study provided fundamental insights into the clinical application of F1 and F3 for the treatment of T-ALL.
Open AccessNovel Ferrocene Derivatives Induce Apoptosis through Mitochondria-Dependent and Cell Cycle Arrest via PI3K/Akt/mTOR Signaling Pathway in T Cell Acute Lymphoblastic Leukemia
T cell acute lymphoblastic leukemia (T-ALL) is one of the most common causes of death in pediatric malignancies. However, the clinical chemotherapy for T-ALL has been limited by numerous side effects, emphasizing that novel anti-T-ALL drugs are urgently needed. Herein, a series of 2-acyl-1-dimethylaminomethyl-ferrocenes for cancer therapy have been evaluated. Among them, F1 and F3 exhibited potent cytotoxicity against T-ALL cell lines, especially Jurkat cells, with low cytotoxicity for normal cells. Further mechanistic studies revealed that F1 and F3 could induce apoptosis in Jurkat cells by destructing mitochondrial membrane, enhancing reactive oxygen species (ROS) generation, decreasing the Bcl-2/Bax ratio, releasing Cytochrome c, and increasing the expression of Cleaved Caspase-9/-3 and Cleaved PARP. Additionally, F1 and F3 could suppress cell proliferation and arrest the cell cycle at G0/G1 phase through the PI3K/Akt/mTOR signaling pathway by down-regulating the expression of CDK6, Cyclin D1, p-Akt, p-GSK-3β, p-mTOR, p-p70 S6K, and up-regulating the expression of P21 and P27, which would also be a possible mechanism. Consequently, ferrocene derivatives F1 and F3 could induce apoptosis through a mitochondria-dependent pathway mediated by ROS, and cell cycle arrest at G0/G1 phase via the PI3K/Akt/mTOR signaling pathway in Jurkat cells. The present study provided fundamental insights into the clinical application of F1 and F3 for the treatment of T-ALL.
- Open Access
- 30 March 2021
- Published by MDPI AG in Marine Drugs
- Vol. 19 (4) , 195
Anti-HBV Activities of Polysaccharides from Thais clavigera (Küster) by In Vitro and In Vivo Study
Hepatitis B virus (HBV) infection remains a major global health problem. It is therefore imperative to develop drugs for anti-hepatitis B with high-efficiency and low toxicity. Attracted by the observations and evidence that the symptoms of some patients from the Southern Fujian, China, suffering from hepatitis B were alleviated after daily eating an edible marine mollusk, Thais clavigera (Küster 1860) (TCK). Water-soluble polysaccharide from TCK (TCKP1) was isolated and characterized. The anti-HBV activity of TCKP1 and its regulatory pathway were investigated on both HepG2.2.15 cell line and HBV transgenic mice. The data obtained from in vitro studies showed that TCKP1 significantly enhanced the production of IFN-α, and reduced the level of HBV antigens and HBV DNA in the supernatants of HepG2.2.15 cells in a dose-dependent manner with low cytotoxicity. The result of the study on the HBV transgenic mice further revealed that TCKP1 significantly decreased the level of transaminases, HBsAg, HBeAg, and HBV DNA in the serum, as well as HBsAg, HBeAg, HBV DNA, and HBV RNA in the liver of HBV transgenic (HBV-Tg) mice. Furthermore, TCKP1 exhibited equivalent inhibitory effect with the positive control tenofovir alafenamide (TAF) on the markers above except for HBV DNA even in low dosage in a mouse model. However, the TCKP1 high-dose group displayed stronger inhibition of transaminases and liver HBsAg, HBeAg, and HBV RNA when compared with those of TAF. Meanwhile, inflammation of the liver was, by pathological observation, relieved in a dose-dependent manner after being treated with TCKP1. In addition, elevated levels of interleukin-12 (IL-12) and interferon γ (IFN-γ), and reduced level of interleukin-4 (IL-4) in the serum were observed, indicating that the anti-HBV effect of TCKP1 was achieved by potentiating immunocyte function and regulating the balance of Th1/Th2 cytokines.
- 30 March 2021
- Published by MDPI AG in Marine Drugs
- Vol. 19 (4) , 195
Open AccessAnti-HBV Activities of Polysaccharides from Thais clavigera (Küster) by In Vitro and In Vivo Study
Hepatitis B virus (HBV) infection remains a major global health problem. It is therefore imperative to develop drugs for anti-hepatitis B with high-efficiency and low toxicity. Attracted by the observations and evidence that the symptoms of some patients from the Southern Fujian, China, suffering from hepatitis B were alleviated after daily eating an edible marine mollusk, Thais clavigera (Küster 1860) (TCK). Water-soluble polysaccharide from TCK (TCKP1) was isolated and characterized. The anti-HBV activity of TCKP1 and its regulatory pathway were investigated on both HepG2.2.15 cell line and HBV transgenic mice. The data obtained from in vitro studies showed that TCKP1 significantly enhanced the production of IFN-α, and reduced the level of HBV antigens and HBV DNA in the supernatants of HepG2.2.15 cells in a dose-dependent manner with low cytotoxicity. The result of the study on the HBV transgenic mice further revealed that TCKP1 significantly decreased the level of transaminases, HBsAg, HBeAg, and HBV DNA in the serum, as well as HBsAg, HBeAg, HBV DNA, and HBV RNA in the liver of HBV transgenic (HBV-Tg) mice. Furthermore, TCKP1 exhibited equivalent inhibitory effect with the positive control tenofovir alafenamide (TAF) on the markers above except for HBV DNA even in low dosage in a mouse model. However, the TCKP1 high-dose group displayed stronger inhibition of transaminases and liver HBsAg, HBeAg, and HBV RNA when compared with those of TAF. Meanwhile, inflammation of the liver was, by pathological observation, relieved in a dose-dependent manner after being treated with TCKP1. In addition, elevated levels of interleukin-12 (IL-12) and interferon γ (IFN-γ), and reduced level of interleukin-4 (IL-4) in the serum were observed, indicating that the anti-HBV effect of TCKP1 was achieved by potentiating immunocyte function and regulating the balance of Th1/Th2 cytokines.
- Open Access
- 18 March 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (6) , 3097
Novel Ferrocene Derivatives Induce G0/G1 Cell Cycle Arrest and Apoptosis through the Mitochondrial Pathway in Human Hepatocellular Carcinoma
In this study, detailed information on hepatocellular carcinoma (HCC) cells (HepG-2, SMMC-7721, and HuH-7) and normal human liver cell L02 treated by ferrocene derivatives (compounds 1, 2 and 3) is provided. The cell viability assay showed that compound 1 presented the most potent and selective anti-HCC activity. Further mechanism study indicated that the proliferation inhibition effect of compound 1 was associated with the cycle arrest at the G0/G1 phase and downregulation of cyclin D1/CDK4. Moreover, compound 1 could induce apoptosis in HCC cells by loss of mitochondrial membrane potential (ΔΨm), accumulation of reactive oxygen species (ROS), decrease in Bcl-2, increase in BAX and Bad, translocation of Cytochrome c, activation of Caspase-9, -3, and cleavage of PARP. These results indicated that compound 1 would be a promising candidate against HCC through G0/G1 cell cycle arrest-related proliferation inhibition and mitochondrial pathway-dependent apoptosis.
- 18 March 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (6) , 3097
Open AccessNovel Ferrocene Derivatives Induce G0/G1 Cell Cycle Arrest and Apoptosis through the Mitochondrial Pathway in Human Hepatocellular Carcinoma
In this study, detailed information on hepatocellular carcinoma (HCC) cells (HepG-2, SMMC-7721, and HuH-7) and normal human liver cell L02 treated by ferrocene derivatives (compounds 1, 2 and 3) is provided. The cell viability assay showed that compound 1 presented the most potent and selective anti-HCC activity. Further mechanism study indicated that the proliferation inhibition effect of compound 1 was associated with the cycle arrest at the G0/G1 phase and downregulation of cyclin D1/CDK4. Moreover, compound 1 could induce apoptosis in HCC cells by loss of mitochondrial membrane potential (ΔΨm), accumulation of reactive oxygen species (ROS), decrease in Bcl-2, increase in BAX and Bad, translocation of Cytochrome c, activation of Caspase-9, -3, and cleavage of PARP. These results indicated that compound 1 would be a promising candidate against HCC through G0/G1 cell cycle arrest-related proliferation inhibition and mitochondrial pathway-dependent apoptosis.
- 1 September 2020
- Published by Hindawi Limited in Aquaculture Research
- Vol. 51 (9) , 3780-3789
Identification of genes expressed differentially in female and male gametes ofSipunculus nudus
The sipunculid wormSipunculus nudusis a widely distributed, commercially important marine mollusc. Oogenesis and sex determination/differentiation are important steps inS. nudusreproduction. However, the molecular mechanisms of oogenesis and sex determination/differentiation inS. nudusare unclear. We successfully generated a high-qualityde novoassembled and annotated transcriptome of oocytes from coelomic fluid (OC), oocytes from nephridium (ON) and spermatozeugmata from coelomic fluid (SC) ofS. nudususing the Illumina sequencing platform. There were 17,720 and 17,030 differentially expressed genes (DEGs) in OC vs. ON and OC vs. SC respectively. KEGG pathway analysis showed that the DEGs in these two groups were enriched in ribosome, thyroid hormone synthesis, apelin signalling pathway and cellular senescence. Critical genes that play essential roles in sex determination/differentiation were found, includingfoxl2,fem-1,dmrt1,ftz-f1andsox9. This may largely contribute to the understanding of the molecular mechanisms of oogenesis and sex determination/differentiation inS. nudusand laid a foundation for further in-depth studies.
- 1 September 2020
- Published by Hindawi Limited in Aquaculture Research
- Vol. 51 (9) , 3780-3789
Identification of genes expressed differentially in female and male gametes ofSipunculus nudus
The sipunculid wormSipunculus nudusis a widely distributed, commercially important marine mollusc. Oogenesis and sex determination/differentiation are important steps inS. nudusreproduction. However, the molecular mechanisms of oogenesis and sex determination/differentiation inS. nudusare unclear. We successfully generated a high-qualityde novoassembled and annotated transcriptome of oocytes from coelomic fluid (OC), oocytes from nephridium (ON) and spermatozeugmata from coelomic fluid (SC) ofS. nudususing the Illumina sequencing platform. There were 17,720 and 17,030 differentially expressed genes (DEGs) in OC vs. ON and OC vs. SC respectively. KEGG pathway analysis showed that the DEGs in these two groups were enriched in ribosome, thyroid hormone synthesis, apelin signalling pathway and cellular senescence. Critical genes that play essential roles in sex determination/differentiation were found, includingfoxl2,fem-1,dmrt1,ftz-f1andsox9. This may largely contribute to the understanding of the molecular mechanisms of oogenesis and sex determination/differentiation inS. nudusand laid a foundation for further in-depth studies.
- Open Access
- 17 July 2020
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 16 (7) , e1008664
AHR is a tunable knob that controls HTLV-1 latency-reactivation switching
Establishing latent infection but retaining the capability to reactivate in certain circumstance is an ingenious tactic for retroviruses to persist in vivo while evading host immune surveillance. Many evidences indicate that Human T-cell leukemia virus type 1 (HTLV-1) is not completely silent in vivo. However, signals that trigger HTLV-1 latency-reactivation switching remain poorly understood. Here, we show that aryl hydrocarbon receptor (AHR), a ligand-activated transcription factor, plays a critical role in HTLV-1 plus-strand expression. Importantly, HTLV-1 reactivation could be tunably manipulated by modulating the level of AHR ligands. Mechanistically, activated AHR binds to HTLV-1 LTR dioxin response element (DRE) site (CACGCATAT) and drives plus-strand transcription. On the other hand, persistent activation of nuclear factor kappa B (NF-κB) pathway constitutes one key prerequisite for AHR overexpression in HTLV-1 infected T-cells, setting the stage for the advent of AHR signaling. Our findings suggest that HTLV-1 might achieve its reactivation in vivo when encountering environmental, dietary, microbial and metabolic cues that induce sufficient AHR signaling. HTLV-1 is considered largely latent in vivo because viral products were rarely detected in freshly isolated PBMCs of infected individuals. However, the existence of strong HTLV-1-specific immune response in most infected individuals suggests that the virus should not be completely silent in vivo. Since viral gene expression plays a critical role in cell transformation and de novo infection, a novel insight into where and how HTLV-1 achieves its reactivation in vivo is essential for developing new therapeutic approaches. AHR is a ligand-activated transcription factor that regulates intricate transcriptional programs in response to environmental, dietary, microbial and metabolic cues. It has been reported that AHR is constitutively overexpressed in HTLV-1-infected T-cells. Nevertheless, the functional role of AHR in HTLV-1 pathogenesis is still obscure. In this study, we show that activated AHR can directly bind to HTLV-1 LTR DRE site (CACGCATAT) and drive HTLV-1 plus-strand transcription. Importantly, HTLV-1 latency-reactivation-latency switching could be manipulated in MT-1 cells by adding and removing additional kynurenine (a well-known AHR ligand). Moreover, we explicate that the persistent NF-κB activation is critical for AHR overexpression in HTLV-1-infected T-cells. These results imply that constitutive AHR overexpression in infected T-cells endues HTLV-1 the potential to reactivate from latency when the level of AHR ligands reaches a certain threshold. Accordingly, we propose that HTLV-1 might achieve its reactivation in certain parts of the body that are prone to accumulate AHR ligands.
- 17 July 2020
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 16 (7) , e1008664
Open AccessAHR is a tunable knob that controls HTLV-1 latency-reactivation switching
Establishing latent infection but retaining the capability to reactivate in certain circumstance is an ingenious tactic for retroviruses to persist in vivo while evading host immune surveillance. Many evidences indicate that Human T-cell leukemia virus type 1 (HTLV-1) is not completely silent in vivo. However, signals that trigger HTLV-1 latency-reactivation switching remain poorly understood. Here, we show that aryl hydrocarbon receptor (AHR), a ligand-activated transcription factor, plays a critical role in HTLV-1 plus-strand expression. Importantly, HTLV-1 reactivation could be tunably manipulated by modulating the level of AHR ligands. Mechanistically, activated AHR binds to HTLV-1 LTR dioxin response element (DRE) site (CACGCATAT) and drives plus-strand transcription. On the other hand, persistent activation of nuclear factor kappa B (NF-κB) pathway constitutes one key prerequisite for AHR overexpression in HTLV-1 infected T-cells, setting the stage for the advent of AHR signaling. Our findings suggest that HTLV-1 might achieve its reactivation in vivo when encountering environmental, dietary, microbial and metabolic cues that induce sufficient AHR signaling. HTLV-1 is considered largely latent in vivo because viral products were rarely detected in freshly isolated PBMCs of infected individuals. However, the existence of strong HTLV-1-specific immune response in most infected individuals suggests that the virus should not be completely silent in vivo. Since viral gene expression plays a critical role in cell transformation and de novo infection, a novel insight into where and how HTLV-1 achieves its reactivation in vivo is essential for developing new therapeutic approaches. AHR is a ligand-activated transcription factor that regulates intricate transcriptional programs in response to environmental, dietary, microbial and metabolic cues. It has been reported that AHR is constitutively overexpressed in HTLV-1-infected T-cells. Nevertheless, the functional role of AHR in HTLV-1 pathogenesis is still obscure. In this study, we show that activated AHR can directly bind to HTLV-1 LTR DRE site (CACGCATAT) and drive HTLV-1 plus-strand transcription. Importantly, HTLV-1 latency-reactivation-latency switching could be manipulated in MT-1 cells by adding and removing additional kynurenine (a well-known AHR ligand). Moreover, we explicate that the persistent NF-κB activation is critical for AHR overexpression in HTLV-1-infected T-cells. These results imply that constitutive AHR overexpression in infected T-cells endues HTLV-1 the potential to reactivate from latency when the level of AHR ligands reaches a certain threshold. Accordingly, we propose that HTLV-1 might achieve its reactivation in certain parts of the body that are prone to accumulate AHR ligands.
- Open Access
- 12 March 2020
- Published by MDPI AG in Marine Drugs
- Vol. 18 (3) , 158
Antioxidant, Hypolipidemic and Hepatic Protective Activities of Polysaccharides from Phascolosoma esculenta
The aims of this study were to investigate the antioxidant, hypolipidemic and hepatic protective effects of Phascolosoma esculenta polysaccharides (PEP). PEP was prepared from Phascolosoma esculenta by enzyme hydrolysis and its characterization was analyzed. The antioxidant activities of PEP were evaluated by the assays of scavenging 1,1-Diphenyl-2-picrylhydrazyl (DPPH), superoxide anion, hydroxyl radicals and chelating ferrous ion in vitro. It showed that PEP could scavenge radicals effectively and had favorable antioxidant activities. In the meantime, the hypolipidemic effect of PEP was investigated in vivo by using mice model fed with high-fat diet with or without PEP treatment. Compared with the hyperlipidemic mice without treatment, the serum levels of total cholesterol (TC) (30.1–35.7%, p < 0.01), triglyceride (TG) (24.5–50.8%, p < 0.01 or p < 0.05), low-density lipoprotein cholesterol (LDL-C) (49.6–56.8%, p < 0.01) and liver levels of TC (21.0–28.4%, p < 0.01), TG (23.8–37.0%, p < 0.01) decreased significantly, whereas serum high-density lipoprotein cholesterol (HDL-C) (47.7–59.9%, p < 0.01 or p < 0.05) increased significantly after treatment with different dosage of PEP (0.2, 0.4 and 0.8 g per kg body weight, respectively). In addition, superoxide dismutase (SOD) (10.2–22.2% and 18.8–26.9%, p < 0.05), glutathione peroxidase (GSH-Px) (11.9–15.4% and 26.6–30.4%, p < 0.05) activities in serum and liver enhanced markedly while aspartate aminotransferase (AST) (18.7–29.6% and 42.4–58.0%, p < 0.05), alanine transaminase (ALT) (42.7–46.0% and 31.2–42.2%, p < 0.05) activities, as well as the levels of malondialdehyde (MDA) (15.9–24.4% and 15.0–16.8%, p < 0.01 or p < 0.05) in serum and liver reduced markedly. Moreover, the histopathological observation of livers indicated that PEP could attenuate liver cell injury. The animal experimental results demonstrated that PEP exerted hypolipidemic and hepatoprotective roles in hyperlipidemic mice. In summary, our results above suggest that PEP might be a potential natural antioxidant and utilized as a therapeutic candidate for hyperlipidemia.
- 12 March 2020
- Published by MDPI AG in Marine Drugs
- Vol. 18 (3) , 158
Open AccessAntioxidant, Hypolipidemic and Hepatic Protective Activities of Polysaccharides from Phascolosoma esculenta
The aims of this study were to investigate the antioxidant, hypolipidemic and hepatic protective effects of Phascolosoma esculenta polysaccharides (PEP). PEP was prepared from Phascolosoma esculenta by enzyme hydrolysis and its characterization was analyzed. The antioxidant activities of PEP were evaluated by the assays of scavenging 1,1-Diphenyl-2-picrylhydrazyl (DPPH), superoxide anion, hydroxyl radicals and chelating ferrous ion in vitro. It showed that PEP could scavenge radicals effectively and had favorable antioxidant activities. In the meantime, the hypolipidemic effect of PEP was investigated in vivo by using mice model fed with high-fat diet with or without PEP treatment. Compared with the hyperlipidemic mice without treatment, the serum levels of total cholesterol (TC) (30.1–35.7%, p < 0.01), triglyceride (TG) (24.5–50.8%, p < 0.01 or p < 0.05), low-density lipoprotein cholesterol (LDL-C) (49.6–56.8%, p < 0.01) and liver levels of TC (21.0–28.4%, p < 0.01), TG (23.8–37.0%, p < 0.01) decreased significantly, whereas serum high-density lipoprotein cholesterol (HDL-C) (47.7–59.9%, p < 0.01 or p < 0.05) increased significantly after treatment with different dosage of PEP (0.2, 0.4 and 0.8 g per kg body weight, respectively). In addition, superoxide dismutase (SOD) (10.2–22.2% and 18.8–26.9%, p < 0.05), glutathione peroxidase (GSH-Px) (11.9–15.4% and 26.6–30.4%, p < 0.05) activities in serum and liver enhanced markedly while aspartate aminotransferase (AST) (18.7–29.6% and 42.4–58.0%, p < 0.05), alanine transaminase (ALT) (42.7–46.0% and 31.2–42.2%, p < 0.05) activities, as well as the levels of malondialdehyde (MDA) (15.9–24.4% and 15.0–16.8%, p < 0.01 or p < 0.05) in serum and liver reduced markedly. Moreover, the histopathological observation of livers indicated that PEP could attenuate liver cell injury. The animal experimental results demonstrated that PEP exerted hypolipidemic and hepatoprotective roles in hyperlipidemic mice. In summary, our results above suggest that PEP might be a potential natural antioxidant and utilized as a therapeutic candidate for hyperlipidemia.
- Open Access
Coagulant Effects and Mechanism of Schefflera heptaphylla (L.) Frodin
Schefflera heptaphylla (L.) Frodin, are commonly used in anti-inflammatory, analgesic, traumatic bleeding and hemostasisas. In this paper, the coagulation effect of the ethanol extract (Set), ethyl acetate phase (Sea) and n-butanol phase (Sbu) was evaluated by prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT) and fibrinogen content (FIB) assays in vitro. Then, Three main lupanine triterpenes (compounds A–C) were isolated and identified from Sea and Sbu by a bioassay-guided method and their structure were identified as 3α-Hydroxy-lup-20(29)-ene-23, 28-dioic acid, betulinic acid 3-O-sulfate and 3α-Hydroxy-lup-20(29)-ene-23, 28-dioic acid 28-O-(α-l-rhamnopyranosyl(1→4)-O-β-d-glucopyranosyl(1→6))-β-d-glucopyranoside) by spectroscopic data analysis. Among of them, compound B was confirmed to have significant coagulant effect in vitro. Furthermore, the pro-coagulation mechanism of S. heptaphylla extracts and compound B were investigated by measuring whole blood viscosity (WBV), plasma viscosity (PV), erythrocyte sedimentetion rate (ESR), pack cell volume (PCV), APTT, PT, TT, and FIB in vivo. Meanwhile, the levels of thromboxane B2 (TXB2), 6-keto prostaglandin F1α (6-keto-PGF1α), endothelial nitric oxide synthase (eNOS) and (endothelin-1) ET-1 were detected. The bleeding time (BT) was tested by tail bleeding method, which proved the traumatic bleeding and hemostasis activities of S. heptaphylla. The pharmacology experiments showed that the Set, Sea, Sbu and compound B has significant pro-coagulation effect. In addition, compound B might be the main constituent of pro-coagulation in S. heptaphylla These results could support the fact that S. heptaphylla could be used traditionally to cure traumatic bleeding, and the pro-coagulation effects were associated with the regulation of vascular endothelium active substance and hemorheology parameters.
Open AccessCoagulant Effects and Mechanism of Schefflera heptaphylla (L.) Frodin
Schefflera heptaphylla (L.) Frodin, are commonly used in anti-inflammatory, analgesic, traumatic bleeding and hemostasisas. In this paper, the coagulation effect of the ethanol extract (Set), ethyl acetate phase (Sea) and n-butanol phase (Sbu) was evaluated by prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT) and fibrinogen content (FIB) assays in vitro. Then, Three main lupanine triterpenes (compounds A–C) were isolated and identified from Sea and Sbu by a bioassay-guided method and their structure were identified as 3α-Hydroxy-lup-20(29)-ene-23, 28-dioic acid, betulinic acid 3-O-sulfate and 3α-Hydroxy-lup-20(29)-ene-23, 28-dioic acid 28-O-(α-l-rhamnopyranosyl(1→4)-O-β-d-glucopyranosyl(1→6))-β-d-glucopyranoside) by spectroscopic data analysis. Among of them, compound B was confirmed to have significant coagulant effect in vitro. Furthermore, the pro-coagulation mechanism of S. heptaphylla extracts and compound B were investigated by measuring whole blood viscosity (WBV), plasma viscosity (PV), erythrocyte sedimentetion rate (ESR), pack cell volume (PCV), APTT, PT, TT, and FIB in vivo. Meanwhile, the levels of thromboxane B2 (TXB2), 6-keto prostaglandin F1α (6-keto-PGF1α), endothelial nitric oxide synthase (eNOS) and (endothelin-1) ET-1 were detected. The bleeding time (BT) was tested by tail bleeding method, which proved the traumatic bleeding and hemostasis activities of S. heptaphylla. The pharmacology experiments showed that the Set, Sea, Sbu and compound B has significant pro-coagulation effect. In addition, compound B might be the main constituent of pro-coagulation in S. heptaphylla These results could support the fact that S. heptaphylla could be used traditionally to cure traumatic bleeding, and the pro-coagulation effects were associated with the regulation of vascular endothelium active substance and hemorheology parameters.